News & Events about Allogene Therapeutics Inc.
Preclinical Efficacy and Safety Results Indicate AlloCAR TDevelopment Candidate Controls Tumor Growth without Off-Tumor/Normal Tissue Toxicity SOUTH SAN FRANCISCO, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc.(Nasdaq: ALLO), a clinical-stage biotechnology company pioneering ...
ALLO-715 is the First Allogeneic anti-BCMA CAR T to Demonstrate Safety, Efficacy and Durability with Off-the-Shelf Convenience in Multiple MyelomaSOUTH SAN FRANCISCO, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc.(Nasdaq: ALLO), a clinical-stage biotechnology company ...
NEW YORK, Jan. 22, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Allogene Therapeutics, Inc. (NASDAQ: ALLO) breached their fiduciary duties to shareholders. The investigation concerns potential ...
Moore Kuehn, PLLC Encourages Investors of Allogene Therapeutics, Inc. to Contact Law Firm Moore Kuehn, PLLC Encourages Investors of Allogene Therapeutics, Inc. to Contact Law Firm PR Newswire NEW YORK, Jan. 5, 2023 NEW YORK, Jan. 5, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm...
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer, today announced that David Chang, M.D., Ph.D., President, Chief Executive ...